Giving Information on Medicinal Products to the General Public — In Search of a Definition to Safeguard the Patient
In: European Journal of Health LawSearch for other papers by Andrea Faeh in
Current site
Google Scholar
Abstract
Information on medicinal products is vital for enabling patients to give informed consent to the use of a specific product. Within the European Union (eu) the debate about how much information about prescription-only medicinal products should be made available to patients has gone on for the past five years with no definite conclusion yet. This contribution assesses the current legislation and the ongoing debate in order to identify the challenges and the prospect of new legislation, and consider its potential implications for the scope for advertising and for patient safety.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
34
See Faeh, supra note 28, p. 41 et seq.
-
36
R. M. Wachter, Understanding Patient Safety (New York: McGraw Hill Medical, 2012), 2nd edition, p. 4.
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 175 | 18 | 0 |
| Full Text Views | 158 | 1 | 0 |
| PDF Views & Downloads | 33 | 3 | 0 |
Giving Information on Medicinal Products to the General Public — In Search of a Definition to Safeguard the Patient
In: European Journal of Health LawSearch for other papers by Andrea Faeh in
Current site
Google Scholar
PubMed
Abstract
Information on medicinal products is vital for enabling patients to give informed consent to the use of a specific product. Within the European Union (eu) the debate about how much information about prescription-only medicinal products should be made available to patients has gone on for the past five years with no definite conclusion yet. This contribution assesses the current legislation and the ongoing debate in order to identify the challenges and the prospect of new legislation, and consider its potential implications for the scope for advertising and for patient safety.
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 175 | 18 | 0 |
| Full Text Views | 158 | 1 | 0 |
| PDF Views & Downloads | 33 | 3 | 0 |